FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
World game at war: why some European nations have threatened a World Cup boycott 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS:CELG), if they purchased the Company’s shares between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Celgene investors should visit us at https://www.claimsfiler.com/cases/view-celgene-corporation-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Celgene and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 19, 2017, the Company disclosed that it was discontinuing trials of its long-touted drug GED-0301 and recording a $1.6 billion impairment charge due to the drug’s failure. Then, on February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (“NDA”) for Ozanimod, another of its leading drug candidates, because “the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.”
On this news, the price of Celgene’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
